An advisory committee voted unanimously Friday to recommend authorizing a COVID-19 vaccine from Johnson & Johnson for use in adults, paving the way for an expected Food and Drug Administration authorization within the next few days. Johnson & Johnson agreed to provide 100 million doses of its single-shot vaccine in the U.S. by June, including 20 million by the end of March. Those doses will add to the 300 million doses Pfizer-BioNTech and Moderna each have promised to deliver by the end of July. The vaccine was shown to be 72% effective in a U.S. trial in which all ethnic, racial and age groups benefited about the same, and was shown to be 85% effective in preventing the most severe disease.